Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.

International journal of antimicrobial agents - 1 Apr 2012

Hirata Yoshihiro, Ohmae Tomoya, Yanai Ayako, Sakitani Kosuke, Hayakawa Yoku, Yoshida Shuntaro, Sugimoto Takafumi, Mitsuno Yuzo, Akanuma Masao, Yamaji Yutaka, Ogura Keiji, Maeda Shin, Koike Kazuhiko

Abstract excerpt

The third-line treatment regimen for Helicobacter pylori after failure of clarithromycin- and metronidazole-based therapies is not yet established. Sitafloxacin (STX) is a quinolone that possesses potent in vitro activity against H. pylori. In this study, the susceptibility of H. pylori isolates to STX was examined and the efficacy of STX-based triple therapy as a third-line regimen was evaluated. STX showed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amoxicillin
Share to DNA Gyrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Fluoroquinolones

Share to Helicobacter Infections

Share to Helicobacter pylori

Share to Hydrogen-Ion Concentration

Share to Inhibitory Concentration 50

Source

Identifiers

PMID: 22321702
DOI: 10.1016/j.ijantimicag.2011.12.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.PMID 22321702Read ↗

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.Semantic proximity Read ↗

Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimensSemantic proximity Read ↗

Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.Semantic proximity Read ↗

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.Semantic proximity Read ↗

Update on quinolone-containing rescue therapies for Helicobacter pylori infection.Semantic proximity Read ↗

Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of <i>Helicobacter pylori</i> with <i>gyrA</i> MutationSemantic proximity Read ↗

Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.Semantic proximity Read ↗

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Semantic proximity Read ↗

Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.Semantic proximity Read ↗

Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.Semantic proximity Read ↗

High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.Semantic proximity Read ↗

Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.